ENG and metastatic neoplasm: The expression of CD105 on tumour-associated blood vessels makes CD105 an interesting target for therapy, as demonstrated by TRC105, the first humanized CD105-targeting antibody used in clinical trials for treatment of advanced or metastatic tumours [14].